Selective osteoblast mitogens can be extracted from prostatic tissue.
Extracts of human prostatic carcinoma and of human benign prostatic hyperplasia were found to exhibit mitogenic activity in freshly isolated rat osteoblasts, rat fibroblasts, and osteoblast-derived osteosarcoma cells. This activity was markedly reduced by tryptic digestion of extracts, indicating its protein nature. Results of bioassay studies suggested that the prostatic material was different from a number of known growth factors. Analysis by reversed-phase high performance liquid chromatography revealed that extracts contained mitogenic activity for osteoblasts that was distinct from fibroblast-stimulating activity. Such osteoblast growth factors could form the basis of the skeletal osteogenic response to metastatic prostatic adenocarcinoma.
D000230:Adenocarcinoma / Q000032:analysis; D000818:Animals; D002455:Cell Division; D002460:Cell Line; D005347:Fibroblasts / Q000166:cytology / Q000378:metabolism; D006133:Growth Substances / Q000494:pharmacology; D006801:Humans; D008297:Male; D008934:Mitogens / Q000302:isolation & purification*; D010006:Osteoblasts / Q000166:cytology* / Q000378:metabolism; D012516:Osteosarcoma / Q000378:metabolism / Q000473:pathology; D011467:Prostate / Q000032:analysis*; D011470:Prostatic Hyperplasia / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000032:analysis*; D051381:Rats; D011919:Rats, Inbred Strains; D013936:Thymidine / Q000378:metabolism; D014020:Tissue Extracts
D006133:Growth Substances; D008934:Mitogens; D014020:Tissue Extracts; D013936:Thymidine